Role of proprotein convertases in prostate cancer progression

Neoplasia (United States)

Volumn 14, Issue 11, 2012, Pages 1032-1042

  Couture, Frédéric ^a   D'Anjou, François ^a   Desjardins, Roxane ^a   Boudreau, François ^b   Day, Robert ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FURIN; KI 67 ANTIGEN; PACE4 PROTEIN; PC7 PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P27; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

EID: 84869191516     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121368     Document Type: Article

References (50)

1. Seidah NG and Prat A (2012). The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11, 367-383.
2. Couture F, D'Anjou F, and Day R (2011). On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomol Concepts 2, 421-438.
3. Hanahan D and Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
4. Fu J, Bassi DE, Zhang J, Li T, Nicolas E, and Klein-Szanto AJ (2012). Transgenic overexpression of the proprotein convertase furin enhances skin tumor growth. Neoplasia 14, 271-282.
5. Dogar AM, Towbin H, and Hall J (2011). Suppression of latent transforming growth factor (TGF)-β1 restores growth inhibitory TGF-β signaling through microRNAs. J Biol Chem 286, 16447-16458.
6. Mahloogi H, Bassi DE, and Klein-Szanto AJ (2002). Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PACE4. Carcinogenesis 23, 565-572.
7. McColl BK, Paavonen K, Karnezis T, Harris NC, Davydova N, Rothacker J, Nice EC, Harder KW, Roufail S, Hibbs ML, et al. (2007). Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J 21, 1088-1098.
8. Bassi DE, Lopez De Cicco R, Cenna J, Litwin S, Cukierman E, and Klein-Szanto AJ (2005). PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res 65, 7310-7319.
9. American cancer statistics (2012). American Cancer Society. Available at: http://www.cancer.org.
10. D'Anjou F, Routhier S, Perreault JP, Latil A, Bonnel D, Fournier I, Salzet M, and Day R (2011). Molecular validation of PACE4 as a target in prostate cancer. Transl Oncol 4, 157-172.
11. Yuasa K, Masuda T, Yoshikawa C, Nagahama M, Matsuda Y, and Tsuji A (2009). Subtilisin-like proprotein convertase PACE4 is required for skeletal muscle differentiation. J Biochem 146, 407-415.
12. Pham NA, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V, Tsao MS, Ho J, and Hedley DW (2007). Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagn Pathol 2, 8.
13. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, and Chung LW (1992). Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 52, 1598-1605.
14. Igawa T, Lin FF, Rao P, and Lin MF (2003). Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Prostate 55, 247-258.
15. Okamoto R, Delansorne R, Wakimoto N, Doan NB, Akagi T, Shen M, Ho QH, Said JW, and Koeffler HP (2012). Inecalcitol, an analog of 1α,25(OH)(2) D(3), induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer 130, 2464-2473.
16. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, and Moul JW (1998). CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 160, 459-465.
17. Chu IM, Hengst L, and Slingerland JM (2008). The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8, 253-267.
18. Rousselet E, Benjannet S, Marcinkiewicz E, Asselin MC, Lazure C, and Seidah NG (2011). Proprotein convertase PC7 enhances the activation of the EGF receptor pathway through processing of the EGF precursor. J Biol Chem 286, 9185-9195.
19. Turner T, Chen P, Goodly LJ, and Wells A (1996). EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis 14, 409-418.
20. Xie H, Turner T, Wang MH, Singh RK, Siegal GP, and Wells A (1995). In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis 13, 407-419.
21. Altieri DC, Languino LR, Lian JB, Stein JL, Leav I, van Wijnen AJ, Jiang Z, and Stein GS (2009). Prostate cancer regulatory networks. J Cell Biochem 107, 845-852.
22. Ware JL (1993). Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev 12, 287-301.
23. Barton J, Blackledge G, and Wakeling A (2001). Growth factors and their receptors: new targets for prostate cancer therapy. Urology 58, 114-122.
24. Dayyani F, Gallick GE, Logothetis CJ, and Corn PG (2011). Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 103, 1665-1675.
25. Ishii K, Imamura T, Iguchi K, Arase S, Yoshio Y, Arima K, Hirano K, and Sugimura Y (2009). Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo. Endocr Relat Cancer 16, 415-428.
26. Lamont KR and Tindall DJ (2011). Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 25, 897-907.
27. Zhu ML and Kyprianou N (2008). Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 15, 841-849.
28. Lokeshwar BL (1999). MMP inhibition in prostate cancer. Ann N Y Acad Sci 878, 271-289.
29. Fornaro M, Manes T, and Languino LR (2001). Integrins and prostate cancer metastases. Cancer Metastasis Rev 20, 321-331.
30. Mueller MM and Fusenig NE (2004). Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4, 839-849.
31. De Wever O, Demetter P, Mareel M, and Bracke M (2008). Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123, 2229-2238.
32. Desmouliere A, Guyot C, and Gabbiani G (2004). The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 48, 509-517.
33. Karlou M, Tzelepi V, and Efstathiou E (2010). Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 7, 494-509.
34. Khatib A-M, Siegfried G, Chrétien M, Metrakos P, and Seidah NG (2002). Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 160, 1921-1935.
35. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, and Klocker H (1996). Regulation of prostatic growth and function by peptide growth factors. Prostate 28, 392-405.
36. Russell PJ, Bennett S, and Stricker P (1998). Growth factor involvement in progression of prostate cancer. Clin Chem 44, 705-723.
37. He X and Zhang J (2006). Why do hubs tend to be essential in protein networks? PLoS Genet 2, e88.
38. Constam DB and Robertson EJ (2000). SPC4/PACE4 regulates a TGFβ signaling network during axis formation. Genes Dev 14, 1146-1155.
39. Malfait AM, Seymour AB, Gao F, Tortorella MD, Le Graverand-Gastineau MP, Wood LS, Doherty M, Doherty S, Zhang W, Arden NK, et al. (2012). A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. Ann Rheum Dis 71, 1042-1048.
40. Andreoiu M and Cheng L (2010). Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 41, 781-793.
41. Vogelstein B and Kinzler KW (2004). Cancer genes and the pathways they control. Nat Med 10, 789-799.
42. Sawyers C (2004). Targeted cancer therapy. Nature 432, 294-297.
43. Roebroek AJ, Umans L, Pauli IG, Robertson EJ, van Leuven F, Van de Ven WJ, and Constam DB (1998). Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase furin. Development 125, 4863-4876.
44. Roebroek AJ, Taylor NA, Louagie E, Pauli I, Smeijers L, Snellinx A, Lauwers A, Van de Ven WJ, Hartmann D, and Creemers JW (2004). Limited redundancy of the proprotein convertase furin in mouse liver. J Biol Chem 279, 53442-53450.
45. De Vos L, Declercq J, Rosas GG, Van Damme B, Roebroek A, Vermorken F, Ceuppens J, van de Ven W, and Creemers J (2008). MMTV-cre-mediated fur inactivation concomitant with PLAG1 proto-oncogene activation delays salivary gland tumorigenesis in mice. Int J Oncol 32, 1073-1083.
46. Huang YH, Lin KH, Liao CH, Lai MW, Tseng YH, and Yeh CT (2012). Furin overexpression suppresses tumor growth and predicts a better postoperative disease-free survival in hepatocellular carcinoma. PLoS One 7, e40738.
47. Lapierre M, Siegfried G, Scamuffa N, Bontemps Y, Calvo F, Seidah NG, and Khatib AM (2007). Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: role of tissue inhibitors of metalloproteinase-1. Cancer Res 67, 9030-9034.
48. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, and Lee C (1998). Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 77, 855-861.
49. Schuurmans AL, Bolt J, Voorhorst MM, Blankenstein RA, and Mulder E (1988). Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int J Cancer 42, 917-922.
50. Schuurmans AL, Bolt J, and Mulder E (1989). Androgen receptor-mediated growth and epidermal growth factor receptor induction in the human prostate cell line LNCaP. Urol Int 44, 71-76.